Neuro-Oncology Nugget: GT-20 Phase 1 Trial — Personalized Neoantigen DNA Vaccine for MGMT Unmethylated Glioblastoma
About this episode
Shahad Abdulsahib discusses a phase 1 clinical trial for a personalized DNA vaccine targeting glioblastoma.
Host/Interviewee: ç, PhD Candidate, UT Health San Antonio Description: Shahad Abdulsahib discusses the GT-20 phase 1 clinical trial evaluating GNOS-PV01, a personalized multivalent neoantigen DNA vaccine administered following surgical resection and radiation in patients with MGMT unmethylated glioblastoma, with findings published in Nature Cancer on May 12th, 2026.
More episodes of Neuro-Oncology: The Podcast
- Author Interview: Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial
- Author Interview Series SNO Podcast May 2026
- Neuro-Oncology Narrative
- Hot Topics: Wellness in Neuro-oncology
- Neuro-Oncology Nugget: Phase 1/2 BT008NA Trial — Focused Ultrasound + Temozolomide for High-Grade Glioma
- SNObound: Career description and advice from Dr. Ryan Cecchi in Neuropathology
Explore listener stats, chart rankings, contacts and more on the Neuro-Oncology: The Podcast podcast page.